Stilbene Chalcone Niacin Derivatives Upregulate ApoA-I
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for increasing ApoA-I levels, such as recombinant ApoA-I or peptides mimicking ApoA-I, face challenges related to stability, delivery, and in vivo half-life, while naturally occurring polyphenols have poor bioavailability and inconsistent efficacy in treating cardiovascular diseases.
Innovation Solution
Development of synthetic stilbene and chalcone compounds, derivatized with covalently bonded niacin, which are administered to modulate ApoA-I expression, thereby increasing HDL levels and reducing LDL and triglycerides, and potentially inhibiting HMG-CoA reductase and ACAT, and enhancing ABCA-I activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If recombinant ApoA-I or peptides mimicking ApoA-I are used to increase ApoA-I levels, then ApoA-I concentration is improved, but stability and in vivo half-life deteriorate
Solution Approach 1:
The patent uses small molecule compounds (stilbenes and chalcones) as intermediaries to indirectly increase ApoA-I levels by upregulating its expression, rather than administering ApoA-I directly. This mediator approach resolves the contradiction by achieving the desired ApoA-I concentration improvement while avoiding the stability and half-life issues of direct ApoA-I administration.
Solution Approach 2:
The patent changes the parameter of ApoA-I production by using small molecule compounds that upregulate ApoA-I expression at the transcriptional or translational level. This parameter change approach allows the body to produce its own stable ApoA-I with appropriate half-life, rather than relying on externally administered unstable recombinant forms.
2Object-affected harmful factors
If naturally occurring polyphenols are used to treat cardiovascular diseases, then antioxidant activity is improved, but bioavailability and efficacy consistency deteriorate
Solution Approach 1:
The patent changes the chemical parameters of polyphenolic compounds by synthesizing stilbene and chalcone derivatives with specific molecular structures, substitution patterns, and physicochemical properties. This parameter optimization improves bioavailability and metabolic stability while maintaining antioxidant activity, resolving the contradiction between beneficial effects and poor bioavailability.
Solution Approach 2:
The patent creates composite molecular structures combining polyphenolic cores with various substituent groups (alkyl, alkoxy, halogen, etc.) to produce stilbene and chalcone derivatives. These composite structures integrate the antioxidant properties of polyphenols with improved pharmacokinetic characteristics, achieving both high antioxidant activity and consistent bioavailability.
Data Source
AI summary
The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.